Charts

News

15 Apr, 2024
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
11 Apr, 2024
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company’s Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Dir
08 Apr, 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
07 Apr, 2024
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations CAMBRIDGE, Mass., Ap
03 Apr, 2024
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 23rd Annual Needham Virtual Healthcare Conference presentation at 8:00am ET
22 Mar, 2024
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
14 Mar, 2024
BDTX Advances in Oncology with Key Clinical Trials and Maintains Strong Cash Position
12 Mar, 2024
Black Diamond Therapeutic (NASDAQ:BDTX) reported its Q4 earnings results on Tuesday, March 12, 2024 at 08:00 AM. Here's what investors ...
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC Oral presentation at AACR annual meeting in April 2024 describing real world evidence of an evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 to benefit patients across multiple lines of therapy Additional planned data releases for 2024 include
05 Mar, 2024
Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutationsCAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced an upcoming oral presentation at the American Association for Cancer Research (AAC
28 Feb, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA.
15 Jan, 2024
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
04 Jan, 2024
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for EGFR mutant/C797S NSCLC BDTX-1535 Phase 2 results for 2L/3L patients with EGFR mutant NSCLC expected Q3 2024 BDTX-1535 Phase 1 clinical trial results and “window of opportunity” data in patients with EGFR mutant GBM expected to be presented at a medical meeting in Q2 2024 BDTX-4933 Phase 1 results in pa
13 Dec, 2023
Gainers Shattuck Labs (NASDAQ:STTK) stock moved upwards by 93.8% to $4.09 during Wednesday's regular session. The company's market cap ...
Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months 19 patients with measurable disease by RANO criteria: 1 patient with confirmed partial response and 8 patients with stable disease BDTX-1535 generally well tolerated, consistent with prior disclosures and no new safety signals observed “Window of opportunity” trial enrol
08 Dec, 2023
Gainers Exicure (NASDAQ:XCUR) stock increased by 63.9% to $0.66 during Friday's pre-market session. The market value of their ...
05 Dec, 2023
Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to...
06 Nov, 2023
Company's cash position stands at $144.3 million, sufficient to fund operations into H1 2025
Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor
25 Oct, 2023
From what we can see, insiders were net buyers in Black Diamond Therapeutics, Inc.'s ( NASDAQ:BDTX ) during the past 12...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $147.46 per unit.
20 Oct, 2023
The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...
14 Oct, 2023
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200mg and 300mg Initial NSCLC expansion cohort data expected in 2024 Initial GBM dose escalation data expected later this year CAMBRIDGE, Mass. and NEW YORK, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology
04 Oct, 2023
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023. The three poster presentations include initial dose escalatio
18 Sep, 2023
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...
Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately. Dr.
12 Sep, 2023
Within the last quarter, Black Diamond Therapeutic (NASDAQ:BDTX) has observed the following analyst ratings: Bullish Somewhat ...
14 Jul, 2023
Analysts have provided the following ratings for Black Diamond Therapeutic (NASDAQ:BDTX) within the last quarter: Bullish Somewhat ...
Upgrades For General Mills Inc (NYSE:GIS), Argus Research upgraded the previous rating of Hold to Buy. For the fourth quarter, General ...
10 Jul, 2023
Gainers Mobilicom Limited (NASDAQ: MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale ...
Although US stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their ...
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading ...
07 Jul, 2023
Although US stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates ...
05 Jul, 2023
Although US stocks closed slightly higher on Monday, there were a few notable insider trades. When insiders purchase shares, it ...
30 Jun, 2023
Tuesday,Black Diamond Therapeutics Inc(NASDAQ: BDTX) announced initial clinical data from the dose escalation portion of ...
Upgrades For Bright Health Group Inc (NYSE:BHG), Nephron Research upgraded the previous rating of Hold to Buy. In the first quarter, ...
Although US stocks closed mostly higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.
29 Jun, 2023
The company announced positive early-trial news for non-small cell lung cancer.
Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock increased by 657.8% to $29.78 during Thursday's pre-market session. The company's ...
Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Did Elon Musk Just Trigger a New Netscape Moment? The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
28 Jun, 2023
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private ...
Upgrades For American States Water Co (NYSE:AWR), UBS upgraded the previous rating of Sell to Neutral. In the first quarter, American ...
In recent trading, shares of Black Diamond Therapeutics Inc (BDTX) have crossed above the average analyst 12-month target price of $3.33, changing hands for $6.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..
Analysts have provided the following ratings for Black Diamond Therapeutic (NASDAQ:BDTX) within the last quarter: Bullish Somewhat ...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow traded ...
27 Jun, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow ...
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement ...
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 238.5% to $6.23 during Tuesday's regular session. Black Diamond ...
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up 0.39% ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips American Rebel (AREB) stock is a hot topic among traders on Tuesday after the self-defense company underwent a reverse stock split. The post American Rebel (AREB) Stock Jumps on 1-for-25 Reverse Split appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Black Diamond Therapeutics (BDTX) stock is seeing massive gains on Tuesday after releasing data from a Phase 1 clinical study. The post Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Did Elon Musk Just Trigger a New Netscape Moment? The $1 Investment You MUST Take Advantage of Right Now The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
Black Diamond Therapeutics Inc(NASDAQ: BDTX) announced initialclinical datafrom the dose escalation portion of the ...
Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 125.0% to $4.14 during Tuesday's pre-market session. The ...
09 May, 2023
Black Diamond Therapeutic (NASDAQ:BDTX) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors ...
13 Mar, 2023
Gainers Provention Bio (NASDAQ:PRVB) stock moved upwards by 260.1% to $24.12 during Monday's regular session. As of 13:30 EST, ...
19 Jan, 2023
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed ...
Gainers BeyondSpring (NASDAQ:BYSI) stock moved upwards by 24.4% to $2.7 during Thursday's regular session. Trading volume for ...
03 Nov, 2022
The Dow Jones closed lower by more than 500 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When ...
01 Nov, 2022
The Dow Jones closed lower by more than 100 points on Monday. Investors, meanwhile, focused on some notable insider trades. When ...
24 Oct, 2022
The Dow Jones traded higher by over 400 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders ...
14 Oct, 2022
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 80.1% to $0.4161 in pre-market trading after declining around ...
16 Aug, 2022
In recent trading, shares of Black Diamond Therapeutics Inc (BDTX) have crossed above the average analyst 12-month target price of $4.00, changing hands for $4.01/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..
09 Aug, 2022
Black Diamond Therapeutic (NASDAQ:BDTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's ...
01 Jul, 2022
U.S. stocks opened slightlylower on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders ...
11 May, 2022
Black Diamond Therapeutic (NASDAQ:BDTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:30 PM. Here's what investors ...
08 Nov, 2021

Related Articles